On 6th October 2014, the ABC TV program '7.30' included a story that misled viewers about our company's HiQCell® treatment.

The report made unsubstantiated assertions, was unbalanced, inaccurate, misleading and drew inferences that, for any reasonable person, were dubious.

In summary, here are the facts:

  1. NRL player Trent Hodkinson was NOT treated with HiQCell and has had no medical association with Regeneus;
  2. Former AFL player Clint Bartram was NOT treated with HiQCell and has had no medical association with Regeneus. He featured in the story and was portrayed in such a way that viewers were likely to draw the inaccurate inference that his failed treatment and subsequently his career ending were associated with Regeneus;
  3. Due to the confidential nature of the physician and patient relationship and Privacy Laws we are unable to comment specifically on the treatment provided to the interviewed female patient. However, based on our knowledge of her case we question the completeness and accuracy of the assertions made in the story with regard to the extent of treatment provided and her reported consequential post-operative pain outcome;
  4. Regeneus does NOT take shortcuts in the evaluation of safety and efficacy of HiQCell, as proposed by an interviewee (and unchallenged by the reporter) in the story. Regeneus has gained extensive evidence over 7 years of scientific and clinical research, as well as safety and efficacy rates on over 400 patients as a results of its OSCARS Clinical Trial and its independent ethics approved HiQCell Joint Registry. These results are available on the HiQCell website. We note that no other Australian stem cell provider provides equivalent information on their procedures;
  5. Regeneus did NOT mislead the ASX in its 27th August announcement about the results of its OSCARS clinical trial;
  6. Regeneus did NOT mislead the ASX in its 27th August announcement with regard to the AFL's approval of the potential use of HiQCell on a case-by-case basis with AFL players;
  7. Regeneus did NOT mislead the AFL in its submission for approval of HiQCell as a treatment option for AFL players under their Prohibited Treatments List. The AFL's approval was based on a comprehensive submission made by Regeneus in July 2014. The information provided to the AFL was comprehensive and properly substantiated.

These facts have been further explained in a more detailed announcement to the ASX, which is available on the Regeneus and HiQCell websites.

Regeneus has confidence in its science and applies rigour to its operations. It is easy - as with any medical procedure - to uncover an individual patient who is dis-satisfied with the outcome of their treatment. That the ABC felt it appropriate to run this story without any balancing comments from satisfied patients and a supportive medical practitioner speaks volumes.

Since the story was aired Regeneus has received many messages of support from HiQCell patients and medical practitioners who are pleased with their treatment outcomes.

distributed by